letter Open AccessTop 1% cited

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

Cancer Cell · 2002 · Vol. 2(2) · pp. 117–125

Neil P. Shah(University of California, Los Angeles)John NicollBhushan Nagar(University of California, Berkeley)M. GorreRonald PaquetteJohn Kuriyan(Howard Hughes Medical Institute)Charles L. Sawyers✉(University of California, Los Angeles)

View via DOI Full-text PDF

Chronic Myeloid Leukemia Treatments Chronic Lymphocytic Leukemia Research Eosinophilic Disorders and SyndromesImatinibMyeloid leukemiaImatinib mesylateTyrosine kinaseCancer researchProtein kinase domainABLBlast CrisisPhiladelphia chromosomeTyrosine-kinase inhibitor

MeSH terms

Imatinib MesylateAllelesAmino Acid SequenceAntineoplastic AgentsBenzamidesClinical Trials as TopicClone CellsDNA Mutational AnalysisHumansModels, MolecularMutationNeoplasm Recurrence, LocalPiperazinesPyrimidinesRecurrence

Citations

1,620

FWCI

33.39

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation